米氮平与其他抗抑郁药在急性期治疗的成人抑郁症:系统回顾和荟萃分析。

文章的细节

引用

复制到剪贴板

渡边N, Omori IM,中川,Cipriani, Barbui C, McGuire H,丘吉尔R,古河道的助教

米氮平与其他抗抑郁药在急性期治疗的成人抑郁症:系统回顾和荟萃分析。

中国精神病学。2008年9月,69(9):1404 - 15所示。

PubMed ID

19193341 (在PubMed

]

文摘

目的:进行全面,系统回顾和荟萃分析的比其他抗抑郁药米氮平的疗效和耐受性的急性期治疗抑郁症。数据源:研究最初确认通过电子搜索Cochrane协作网的抑郁、焦虑和神经症对照试验注册2006年6月。使用以下搜索条件:抑制*,dysthymi *,适应障碍*,情绪障碍,情感障碍,情感症状,和米氮平。没有语言的限制。包括研究的参考书目,以前有关系统评价和试验注册也手搜索。制药公司和该领域的专家联系更多的研究。研究选择:25个随机对照试验是包括在内。数据提取:两个独立评估员检查试验的质量和提取数据在意向性治疗基础上。数据合成:主要结果测量指标是相对危险度(RR)的响应(99% CIs)在急性期治疗的结论。与治疗的早期阶段(2周),米氮平之间没有显著差异,三环抗抑郁药的反应(RR = 0.90, 99% CI = 0.69 ~ 1.18, p = .30[8试验导致这个结果])或缓解(RR = 0.87, 99% CI = 0.52 ~ 1.47, p = 50[8]试验)结果,但米氮平是优于选择性5 -羟色胺再摄取抑制剂(SSRIs)方面的响应(RR = 1.36, 99% CI = 1.13 ~ 1.64, p <。试验[12])和缓解(RR = 1.68, 99% CI = 1.20 ~ 2.36, p <。试验[12])。 In the subgroup analyses, mirtazapine significantly produced more response than paroxetine (RR = 2.02, 99% CI = 1.09 to 3.75, p = .003 [3 trials]) and venlafaxine (RR = 1.77, 99% CI = 1.08 to 2.89, p = .003 [2 trials]). At the end of acute-phase treatment (6-12 weeks, all trials), no significant differences were observed in the efficacy outcomes. No significant differences were observed between mirtazapine and the other antidepressants in terms of either the total number of dropouts due to any reason (21 trials) or the total number of dropouts due to the development of side effect (23 trials) during the trials. CONCLUSIONS: Although mirtazapine is likely to have a faster onset of action than SSRIs, no significant differences were observed at the end of 6 to 12 weeks' treatment. Clinicians should focus on other practically relevant considerations to tailor treatment to best fit the needs of individual patients.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

米氮平